hydroxyurea has been researched along with SC Disease in 17 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "For children and adults with HbSC disease, PIVOT will determine the safety of hydroxyurea and identify measurable changes in laboratory and clinical parameters, suitable for future prospective testing in a definitive multi-centre phase III clinical trial." | 9.69 | Prospective identification of variables as outcomes for treatment (PIVOT): study protocol for a randomised, placebo-controlled trial of hydroxyurea for Ghanaian children and adults with haemoglobin SC disease. ( Amissah-Arthur, KN; Dei-Adomakoh, YA; Dzefi-Tettey, K; Lane, AC; Latham, TS; Segbefia, CI; Smart, LR; Stuber, SE; Ware, RE, 2023) |
| "Studies in adults with Hb SC disease suggested that hydroxyurea reduced hemolysis and increased red cell hydration." | 7.70 | Maximum urine concentrating ability in children with Hb SC disease: effects of hydroxyurea. ( Baliga, R; Brugnara, C; Hogan, S; Iyer, R; Kirchner, K; Nagel, RL; Steinberg, MH, 2000) |
| "For children and adults with HbSC disease, PIVOT will determine the safety of hydroxyurea and identify measurable changes in laboratory and clinical parameters, suitable for future prospective testing in a definitive multi-centre phase III clinical trial." | 5.69 | Prospective identification of variables as outcomes for treatment (PIVOT): study protocol for a randomised, placebo-controlled trial of hydroxyurea for Ghanaian children and adults with haemoglobin SC disease. ( Amissah-Arthur, KN; Dei-Adomakoh, YA; Dzefi-Tettey, K; Lane, AC; Latham, TS; Segbefia, CI; Smart, LR; Stuber, SE; Ware, RE, 2023) |
| "Hydroxyurea is an excellent therapeutic agent for the pharmacological induction of HbF in patients with sickle cell disease (SCD)." | 5.43 | Original Research: Use of hydroxyurea and phlebotomy in pediatric patients with hemoglobin SC disease. ( Sheehan, VA; Summarell, CC, 2016) |
| "Studies in adults with Hb SC disease suggested that hydroxyurea reduced hemolysis and increased red cell hydration." | 3.70 | Maximum urine concentrating ability in children with Hb SC disease: effects of hydroxyurea. ( Baliga, R; Brugnara, C; Hogan, S; Iyer, R; Kirchner, K; Nagel, RL; Steinberg, MH, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.76) | 18.2507 |
| 2000's | 4 (23.53) | 29.6817 |
| 2010's | 7 (41.18) | 24.3611 |
| 2020's | 4 (23.53) | 2.80 |
| Authors | Studies |
|---|---|
| Ghunney, WK | 1 |
| Asare, EV | 1 |
| Ayete-Nyampong, JB | 1 |
| Oppong, SA | 1 |
| Rodeghier, M | 1 |
| DeBaun, MR | 1 |
| Olayemi, E | 1 |
| D'Alessandro, A | 1 |
| Nouraie, SM | 1 |
| Zhang, Y | 1 |
| Cendali, F | 1 |
| Gamboni, F | 1 |
| Reisz, JA | 1 |
| Zhang, X | 1 |
| Bartsch, KW | 1 |
| Galbraith, MD | 1 |
| Espinosa, JM | 1 |
| Gordeuk, VR | 1 |
| Gladwin, MT | 1 |
| Smart, LR | 1 |
| Segbefia, CI | 1 |
| Latham, TS | 1 |
| Stuber, SE | 1 |
| Amissah-Arthur, KN | 1 |
| Dzefi-Tettey, K | 1 |
| Lane, AC | 1 |
| Dei-Adomakoh, YA | 1 |
| Ware, RE | 1 |
| Zhao, Y | 1 |
| Maule, J | 1 |
| Li, Y | 1 |
| Neff, J | 1 |
| McCall, CM | 1 |
| Hao, T | 1 |
| Yang, W | 1 |
| Rehder, C | 1 |
| Yang, LH | 1 |
| Wang, E | 1 |
| da Guarda, CC | 1 |
| Yahouédéhou, SCMA | 1 |
| Santiago, RP | 1 |
| Neres, JSDS | 1 |
| Fernandes, CFL | 1 |
| Aleluia, MM | 1 |
| Figueiredo, CVB | 1 |
| Fiuza, LM | 1 |
| Carvalho, SP | 1 |
| Oliveira, RM | 1 |
| Fonseca, CA | 1 |
| Ndidi, US | 1 |
| Nascimento, VML | 1 |
| Rocha, LC | 1 |
| Goncalves, MS | 1 |
| Nevitt, SJ | 1 |
| Jones, AP | 1 |
| Howard, J | 1 |
| Naessens, V | 1 |
| Ward, R | 1 |
| Kuo, KHM | 1 |
| Summarell, CC | 1 |
| Sheehan, VA | 1 |
| Carmel, R | 1 |
| Bellevue, R | 1 |
| Kelman, Z | 1 |
| Wang, W | 1 |
| Brugnara, C | 3 |
| Snyder, C | 1 |
| Wynn, L | 1 |
| Rogers, Z | 1 |
| Kalinyak, K | 1 |
| Brown, C | 1 |
| Qureshi, A | 1 |
| Bigelow, C | 1 |
| Neumayr, L | 1 |
| Smith-Whitley, K | 1 |
| Chui, DH | 1 |
| Delahunty, M | 1 |
| Woolson, R | 1 |
| Steinberg, M | 1 |
| Telen, M | 1 |
| Kesler, K | 1 |
| Yates, AM | 1 |
| Dedeken, L | 1 |
| Smeltzer, MP | 1 |
| Lebensburger, JD | 1 |
| Wang, WC | 1 |
| Robitaille, N | 1 |
| Stuart, A | 1 |
| Jones, SM | 1 |
| Walker, LJ | 1 |
| Bridges, KR | 1 |
| Barabino, GD | 1 |
| Cho, MR | 1 |
| Christoph, GW | 1 |
| Dover, G | 1 |
| Ewenstein, BM | 1 |
| Golan, DE | 1 |
| Guttmann, CR | 1 |
| Hofrichter, J | 1 |
| Mulkern, RV | 1 |
| Zhang, B | 1 |
| Eaton, WA | 1 |
| Udden, MM | 1 |
| Lo, MN | 1 |
| Sears, DA | 1 |
| Iyer, R | 1 |
| Baliga, R | 1 |
| Nagel, RL | 1 |
| Kirchner, K | 1 |
| Hogan, S | 1 |
| Steinberg, MH | 1 |
| Hagar, RW | 1 |
| Vichinsky, EP | 1 |
| Davies, S | 1 |
| Olujohungbe, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effectiveness of Hydroxyurea and Magnesium Pidolate Alone and in Combination in Hemoglobin SC Disease: A Phase II Trial[NCT00532883] | Phase 2 | 44 participants (Actual) | Interventional | 2007-01-31 | Terminated (stopped due to Enrollment has been terminated due to a slow rate of enrollment.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
An individuals' percentage of red blood cells with density greater than 41 g/dL as measured by Advia. (NCT00532883)
Timeframe: measured 2 months after initiation of treatment
| Intervention | percent of cells (Mean) |
|---|---|
| Hydroxyurea/Magnesium | 12.09 |
| Hydroxyurea/Mg Placebo | 11.16 |
| HU Placebo/Magnesium | 10.49 |
| HU Placebo/Mg Placebo | 12.79 |
3 reviews available for hydroxyurea and SC Disease
| Article | Year |
|---|---|
Hydroxyurea (hydroxycarbamide) for sickle cell disease.
Topics: Adult; Anemia, Sickle Cell; Antisickling Agents; Chelation Therapy; Child; Erythrocyte Transfusion; | 2017 |
Major changes in sickle cell disease.
Topics: Blood Transfusion; Bone Marrow Transplantation; Deferoxamine; Enzyme Inhibitors; Fetal Hemoglobin; G | 2000 |
Hydroxyurea for sickle cell disease.
Topics: Antisickling Agents; Hemoglobin SC Disease; Humans; Hydroxyurea; Randomized Controlled Trials as Top | 2001 |
2 trials available for hydroxyurea and SC Disease
| Article | Year |
|---|---|
Prospective identification of variables as outcomes for treatment (PIVOT): study protocol for a randomised, placebo-controlled trial of hydroxyurea for Ghanaian children and adults with haemoglobin SC disease.
Topics: Adult; Anemia, Sickle Cell; Child; Ghana; Hemoglobin SC Disease; Humans; Hydroxyurea; Quality of Lif | 2023 |
The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial.
Topics: Adolescent; Adult; Antisickling Agents; Biomarkers; Cell Adhesion; Child; Child, Preschool; Double-B | 2011 |
12 other studies available for hydroxyurea and SC Disease
| Article | Year |
|---|---|
Most adults with severe HbSC disease are not treated with hydroxyurea.
Topics: Adult; Anemia, Sickle Cell; Cohort Studies; Hemoglobin SC Disease; Hemoglobin, Sickle; Humans; Hydro | 2023 |
Metabolic signatures of cardiorenal dysfunction in plasma from sickle cell patients as a function of therapeutic transfusion and hydroxyurea treatment.
Topics: Anemia, Sickle Cell; Bile Acids and Salts; Hemoglobin SC Disease; Hemoglobin, Sickle; Hemolysis; Hum | 2023 |
Sequential development of human herpes virus 8-positive diffuse large B-cell lymphoma and chronic myelomonocytic leukemia in a 59 year old female patient with hemoglobin SC disease.
Topics: Antisickling Agents; Cell Transformation, Neoplastic; Disease Progression; Fatal Outcome; Female; He | 2019 |
Sickle cell disease: A distinction of two most frequent genotypes (HbSS and HbSC).
Topics: Adolescent; Anemia, Sickle Cell; Biomarkers; Child; Cross-Sectional Studies; Female; Folic Acid; Gen | 2020 |
A proposed treatment algorithm for adults with Haemoglobin SC disease.
Topics: Acute Chest Syndrome; Adolescent; Adult; Aged; Algorithms; Antisickling Agents; Female; Follow-Up St | 2018 |
Original Research: Use of hydroxyurea and phlebotomy in pediatric patients with hemoglobin SC disease.
Topics: Antisickling Agents; Child; Combined Modality Therapy; Female; Hemoglobin SC Disease; Humans; Hydrox | 2016 |
Low cobalamin levels associated with sickle cell disease: Contrasting origins and clinical meanings in two instructive patients.
Topics: Adult; Anemia, Pernicious; Anemia, Sickle Cell; Autoantibodies; Depression; Female; Folic Acid; Gast | 2010 |
Hydroxyurea treatment of children with hemoglobin SC disease.
Topics: Acute Chest Syndrome; Adolescent; Antisickling Agents; Child; Child, Preschool; Female; Hemoglobin S | 2013 |
Insights into elevated distortion product otoacoustic emissions in sickle cell disease: comparisons of hydroxyurea-treated and non-treated young children.
Topics: Adolescent; Antisickling Agents; Auditory Threshold; Case-Control Studies; Child; Cochlea; Female; H | 2006 |
A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy.
Topics: Adult; Anion Exchange Protein 1, Erythrocyte; Cell Adhesion; Chlorides; Endothelium, Vascular; Eryth | 1996 |
Successful hydroxyurea treatment of a patient with SD hemoglobinopathy.
Topics: Anemia, Sickle Cell; Female; Hemoglobin SC Disease; Hemoglobins, Abnormal; Humans; Hydroxyurea; Midd | 1999 |
Maximum urine concentrating ability in children with Hb SC disease: effects of hydroxyurea.
Topics: Adolescent; Adult; Antisickling Agents; Child; Female; Hemoglobin SC Disease; Humans; Hydroxyurea; K | 2000 |